Compare HIMX & BHVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HIMX | BHVN |
|---|---|---|
| Founded | 2001 | 2013 |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.0B |
| IPO Year | 2006 | 2022 |
| Metric | HIMX | BHVN |
|---|---|---|
| Price | $13.75 | $14.28 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 14 |
| Target Price | N/A | ★ $29.08 |
| AVG Volume (30 Days) | 1.5M | ★ 1.9M |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | ★ 3.23% | N/A |
| EPS Growth | N/A | ★ 26.08 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.94 | N/A |
| Revenue Next Year | $7.79 | N/A |
| P/E Ratio | $14.99 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.85 | $7.48 |
| 52 Week High | $25.09 | $18.57 |
| Indicator | HIMX | BHVN |
|---|---|---|
| Relative Strength Index (RSI) | 49.52 | 52.28 |
| Support Level | $12.49 | $13.84 |
| Resistance Level | $16.07 | $17.01 |
| Average True Range (ATR) | 0.72 | 0.76 |
| MACD | 0.26 | -0.15 |
| Stochastic Oscillator | 80.34 | 48.50 |
Himax Technologies Inc is a semiconductor solution provider dedicated to display imaging processing technologies. It operates through the Driver Integrated Circuit and Non-Driver Products segments. The majority of the firm's revenue is derived from the Driver Integrated Circuit segment. It offers display driver ICs and timing controllers used in TVs, laptops, monitors, mobile phones, tablets, digital cameras, virtual reality (VR) devices, and many other consumer electronics devices. It also designs and provides controllers for touch sensor displays, in-cell Touch and Display Driver Integration single-chip solutions, LED driver ICs, power management ICs, and scaler products for monitors and projectors. Geographically, it generates the majority of its revenue from China.
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder and others. Its pipeline products include: BHV-2000, BHV-7000, BHV-2100, BHV-8000, BHV-1310, BHV-1300, BHV-1400, BHV-1600, BHV-1530, and BHV-1500.